# A Study of LY2623091 in Participants With High Blood Pressure

Study · id `cardio:ct-nct02194465` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02194465](<https://clinicaltrials.gov/study/NCT02194465>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02194465

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

## Technical summary

Registry record NCT02194465. Randomized; double masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-03 (actual). Results posted on 2020-06-26.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 304 participants (enrolled count; ClinicalTrials.gov record NCT02194465, source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)
- Start date: 2014-08 (registry gives no type) (ClinicalTrials.gov record NCT02194465, source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)
- Primary completion: 2015-03 (actual) (ClinicalTrials.gov record NCT02194465, source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)
- Completion: 2015-03 (actual) (ClinicalTrials.gov record NCT02194465, source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)
- Results first posted: 2020-06-26 (ClinicalTrials.gov record NCT02194465, source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)
- Countries: United States; Canada; Puerto Rico (ClinicalTrials.gov record NCT02194465, source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02194465-2020-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of LY2623091 in Participants With High Blood Pressure
- Condition: Primary Hypertension
- Intervention (Drug): LY2623091
- Intervention (Drug): Tadalafil
- Intervention (Drug): Spironolactone
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 8c37d300d537ac772e40a5af60e4e0711ee91828aa1412ae278eaf333cade7c5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
